# THE SCOPE OF THIS TASK ORDER IS (1). PRODUCTION OF A DRUG SUBSTANCE, (2) CONVERSION OF DRUG SUBSTANCE TO DRUG PRODUCT, (3) FILLING DRUG PRODUCT INTO APPLICATORS TO BE USED IN THE CLINICAL TRIALS, AND

> **NIH NIH N02** · MIDWEST RESEARCH INSTITUTE · 2024 · $1,866,116

## Abstract

The clinical product being produced under this task order is a biotherapeutic drug product.  The product to be produced under this task order is a live biotherapeutic, Lactobacillus crispatus to be used for correcting microflora in women with bacterial vaginosis and vaginal dysbiosis.  This results in a vaginal microbiota dominated with lactobacillus which helps in lowering risk of cervical dysplasia and cancer.

## Key facts

- **NIH application ID:** 11219071
- **Project number:** 75N91023D00010-0-759102400001-1
- **Recipient organization:** MIDWEST RESEARCH INSTITUTE
- **Principal Investigator:** JON WHITE
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,866,116
- **Award type:** —
- **Project period:** 2024-09-18 → 2026-09-17

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11219071

## Citation

> US National Institutes of Health, RePORTER application 11219071, THE SCOPE OF THIS TASK ORDER IS (1). PRODUCTION OF A DRUG SUBSTANCE, (2) CONVERSION OF DRUG SUBSTANCE TO DRUG PRODUCT, (3) FILLING DRUG PRODUCT INTO APPLICATORS TO BE USED IN THE CLINICAL TRIALS, AND (75N91023D00010-0-759102400001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11219071. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*